Levetiracetam Hormosan

Levetiracetam, the active ingredient in Levetiracetam Hormosan, is an anticonvulsant presented as an oral tablet for systemic administration. It is used to control partial, generalized tonic‑clonic and myoclonic seizures in patients diagnosed with epilepsy, helping to reduce seizure frequency and improve quality of life.

GNH USA supplies Levetiracetam Hormosan as a licensed, Good Distribution Practice‑compliant pharmaceutical product, providing reliable global sourcing for hospitals, pharmacies and clinics. The company follows stringent quality standards and offers regulatory‑approved documentation to support international procurement and patient care.

Levetiracetam is an antiepileptic drug that reduces neuronal excitability in seizure disorders.

Partial seizures: decreases frequency of focal onset seizures in adults and children. Generalized tonic‑clonic seizures: helps prevent convulsive episodes in patients with primary generalized epilepsy. Myoclonic seizures: reduces rapid jerking movements associated with juvenile myoclonic epilepsy. Adjunct therapy: used as add‑on treatment when seizures are not adequately controlled by other agents.

Levetiracetam may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness - Somnolence - Fatigue - Irritability - Headache - Nausea

Serious or Rare Side Effects: - Severe allergic reactions such as Stevens‑Johnson syndrome - Psychiatric disturbances including aggression, depression, or suicidal thoughts - Rash or multi‑organ hypersensitivity - Blood dyscrasias such as leukopenia or thrombocytopenia

Levetiracetam requires careful monitoring in several clinical situations.

Renal impairment: dose adjustment may be required in patients with reduced kidney function. Hepatic dysfunction: monitor liver enzymes in patients with liver disease. Psychiatric history: observe for mood changes or behavioral disturbances. Concomitant CNS depressants: use caution as additive sedation may occur. Pregnancy and lactation: risk unknown; weigh benefits against potential risks. Store at ambient temperature: keep below 25 °C, protect from moisture and light in original container.

Levetiracetam can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Carbamazepine: may reduce levetiracetam plasma levels, decreasing efficacy. - Phenytoin: may increase risk of neurotoxicity when combined. - Phenobarbital: may lower levetiracetam concentrations.

Moderate Interactions (Monitor Closely): - Alcohol: additive CNS depression may occur. - Other antiepileptics (valproate, lamotrigine): monitor seizure control. - Renal excretion inhibitors (cimetidine): may increase levetiracetam exposure.